Oral delivery is by far the most preferred drug administration route for patients. But limited oral absorption of biologics such as peptides, proteins, RNAs, and antibodies has been a major challenge. The BIONDD capsule is swallowed and, when exposed to liquids in the stomach, a mechanism for the insertion of active substances into the stomach wall is triggered allowing for the effective distribution of biomacromolecules to the bloodstream and circulation. The BIONDD technology fits into a conventional size 0 capsule giving it an attractive small size for effective, safe, and convenient oral administration to further improve patient compliance and treatment. Oral dosing with the BIONDD capsule of liraglutide has the same exposure as subcutaneous injection in dogs demonstrating that stomach intra-wall delivery with the BIONDD technology has the potential to transform injectable pharmaceutical products into convenient oral capsules.
Learning Objectives:
Recognize stomach intra-wall delivery as an effective route of administration with the potential to replace injections.
Interpret the plasma liraglutide exposure profiles after oral administration with the BIONDD device.